SG159504A1 - Crystalline composition containing escitalopram oxalate - Google Patents

Crystalline composition containing escitalopram oxalate

Info

Publication number
SG159504A1
SG159504A1 SG201000567-6A SG2010005676A SG159504A1 SG 159504 A1 SG159504 A1 SG 159504A1 SG 2010005676 A SG2010005676 A SG 2010005676A SG 159504 A1 SG159504 A1 SG 159504A1
Authority
SG
Singapore
Prior art keywords
escitalopram oxalate
composition containing
crystalline particles
crystalline composition
escitalopram
Prior art date
Application number
SG201000567-6A
Inventor
Kim Bijstrup Jensen
Rikke Eva Humble
Ken Liljegren
Troels Volsgaard Christensen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SG159504A1 publication Critical patent/SG159504A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

The present invention discloses crystalline particles of escitalopram oxalate which either have a broad particle size distribution or comprise at least 0.01 % (w/w) of Z-4-(4-dimethylamino-l-(4-fluorophenyl)-but-l-enyl)-3- hydroxymethyl-benzonitrile, said particles being suitable for use in direct compression. Furthermore, the invention discloses a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate as well as methods for manufacture of such crystalline particles of escitalopram oxalate Finally, the invention provides a method for reduction of the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram.
SG201000567-6A 2004-03-05 2005-02-21 Crystalline composition containing escitalopram oxalate SG159504A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200400382 2004-03-05

Publications (1)

Publication Number Publication Date
SG159504A1 true SG159504A1 (en) 2010-03-30

Family

ID=36607154

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201000567-6A SG159504A1 (en) 2004-03-05 2005-02-21 Crystalline composition containing escitalopram oxalate

Country Status (9)

Country Link
KR (1) KR20060126587A (en)
CN (3) CN1925844A (en)
AR (1) AR047749A1 (en)
IL (1) IL177504A0 (en)
MY (1) MY142756A (en)
PE (1) PE20051162A1 (en)
SG (1) SG159504A1 (en)
TW (1) TW200605916A (en)
ZA (1) ZA200607382B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114763343A (en) * 2021-01-14 2022-07-19 浙江华海药业股份有限公司 Method for purifying citalopram or S-citalopram
CN113663356B (en) * 2021-08-23 2022-09-23 广西埃索凯新材料科技有限公司 Crystallization impurity removal monitoring system applied to manganese sulfate production

Also Published As

Publication number Publication date
AR047749A1 (en) 2006-02-15
ZA200607382B (en) 2008-05-28
TW200605916A (en) 2006-02-16
CN101492435A (en) 2009-07-29
PE20051162A1 (en) 2006-01-16
CN101492436A (en) 2009-07-29
IL177504A0 (en) 2006-12-10
CN1925844A (en) 2007-03-07
KR20060126587A (en) 2006-12-07
MY142756A (en) 2010-12-31

Similar Documents

Publication Publication Date Title
TW200519075A (en) Novel compounds
BR0206164A (en) Escitalopram oxalate crystalline particles, method for the production of escitalopram oxalate crystalline particles, and solid unit dosage form
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
TW200745003A (en) Novel compounds
UA86595C2 (en) Gamma-crystalline form of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
MXPA04004956A (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders.
MX2009005455A (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs.
MXPA04003858A (en) Mch antagonists for the treatment of obesity.
UA100228C2 (en) Pharmaceutical composition containing a tetrahydrofolic acid
WO2011065800A3 (en) Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same
WO2006002140A3 (en) Compositions comprising amphotericin b
DE60110054D1 (en) Cardioprotektive phosphonate
WO2010131922A3 (en) Amide compound, preparation method thereof and pharmaceutical composition comprising same
WO2007071915A3 (en) Pharmaceutical product comprising porous silicon
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EA200601641A1 (en) CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE
HK1126194A1 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
SG159504A1 (en) Crystalline composition containing escitalopram oxalate
GB0029774D0 (en) Clay composition
AU2003251729A1 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
WO2006030301A8 (en) Cilostazol- containing pharmaceutical composition based on particles of less than 50 micrometers
WO2009046056A3 (en) Dental composition containing glass beads, process for production and use therefof
MXPA06000460A (en) IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES.